Which has better valuation & earnings, TNDM or MMED?

MiniMed Group has higher revenue and earnings than Tandem Diabetes Care. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tandem Diabetes Care $1.01B 0.97 -$204.71M -$1.40 N/A MiniMed Group $2.99B 1.29 N/A N/A N/A

Tandem Diabetes Care (TNDM) Competitors

$14.41 +0.07 (+0.49%)

As of 04:00 PM Eastern

Compare

TNDM vs. LIVN, MMED, NVST, IRTC, and WRBY

Should you buy Tandem Diabetes Care stock or one of its competitors? MarketBeat compares Tandem Diabetes Care with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tandem Diabetes Care include LivaNova (LIVN), MiniMed Group (MMED), Envista (NVST), iRhythm Technologies (IRTC), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.

How does Tandem Diabetes Care compare to LivaNova?

Tandem Diabetes Care (NASDAQ:TNDM) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Tandem Diabetes Care has higher earnings, but lower revenue than LivaNova. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	0.97	-$204.71M	-$1.40	N/A
LivaNova	$1.39B	3.11	-$242.47M	$1.95	40.35

Tandem Diabetes Care has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Tandem Diabetes Care currently has a consensus price target of $29.13, suggesting a potential upside of 102.12%. LivaNova has a consensus price target of $80.75, suggesting a potential upside of 2.63%. Given Tandem Diabetes Care's higher possible upside, research analysts clearly believe Tandem Diabetes Care is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.45
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

LivaNova has a net margin of 7.48% compared to Tandem Diabetes Care's net margin of -9.20%. LivaNova's return on equity of 16.48% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
LivaNova	7.48%	16.48%	7.59%

97.6% of LivaNova shares are held by institutional investors. 2.1% of Tandem Diabetes Care shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Tandem Diabetes Care and Tandem Diabetes Care both had 1 articles in the media. LivaNova's average media sentiment score of 1.04 beat Tandem Diabetes Care's score of 0.00 indicating that LivaNova is being referred to more favorably in the news media.

Company	Overall Sentiment
Tandem Diabetes Care	Neutral
LivaNova	Positive

Summary

LivaNova beats Tandem Diabetes Care on 10 of the 16 factors compared between the two stocks.

How does Tandem Diabetes Care compare to MiniMed Group?

Tandem Diabetes Care (NASDAQ:TNDM) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Tandem Diabetes Care currently has a consensus price target of $29.13, indicating a potential upside of 102.12%. MiniMed Group has a consensus price target of $21.33, indicating a potential upside of 55.26%. Given Tandem Diabetes Care's higher possible upside, equities research analysts clearly believe Tandem Diabetes Care is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.45
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

MiniMed Group has a net margin of 0.00% compared to Tandem Diabetes Care's net margin of -9.20%. MiniMed Group's return on equity of 0.00% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
MiniMed Group	N/A	N/A	N/A

19.7% of MiniMed Group shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 2.2% of MiniMed Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, MiniMed Group had 1 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 2 mentions for MiniMed Group and 1 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 0.00 equaled MiniMed Group'saverage media sentiment score.

Company	Overall Sentiment
Tandem Diabetes Care	Neutral
MiniMed Group	Neutral

MiniMed Group has higher revenue and earnings than Tandem Diabetes Care.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	0.97	-$204.71M	-$1.40	N/A
MiniMed Group	$2.99B	1.29	N/A	N/A	N/A

Summary

MiniMed Group beats Tandem Diabetes Care on 10 of the 12 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Envista?

Envista (NYSE:NVST) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Envista currently has a consensus price target of $28.67, suggesting a potential upside of 13.17%. Tandem Diabetes Care has a consensus price target of $29.13, suggesting a potential upside of 102.12%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.45

In the previous week, Tandem Diabetes Care had 1 more articles in the media than Envista. MarketBeat recorded 1 mentions for Tandem Diabetes Care and 0 mentions for Envista. Envista's average media sentiment score of 0.89 beat Tandem Diabetes Care's score of 0.00 indicating that Envista is being referred to more favorably in the media.

Company	Overall Sentiment
Envista	Positive
Tandem Diabetes Care	Neutral

Envista has a net margin of 2.41% compared to Tandem Diabetes Care's net margin of -9.20%. Envista's return on equity of 7.11% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

Envista has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.52	$47M	$0.41	61.78
Tandem Diabetes Care	$1.01B	0.97	-$204.71M	-$1.40	N/A

Envista has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Summary

Envista beats Tandem Diabetes Care on 9 of the 15 factors compared between the two stocks.

How does Tandem Diabetes Care compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

iRhythm Technologies has higher earnings, but lower revenue than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.84	-$44.55M	-$0.86	N/A
Tandem Diabetes Care	$1.01B	0.97	-$204.71M	-$1.40	N/A

iRhythm Technologies currently has a consensus target price of $187.38, indicating a potential upside of 70.16%. Tandem Diabetes Care has a consensus target price of $29.13, indicating a potential upside of 102.12%. Given Tandem Diabetes Care's higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.45

In the previous week, iRhythm Technologies had 5 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 6 mentions for iRhythm Technologies and 1 mentions for Tandem Diabetes Care. iRhythm Technologies' average media sentiment score of 0.65 beat Tandem Diabetes Care's score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
iRhythm Technologies	Positive
Tandem Diabetes Care	Neutral

iRhythm Technologies has a net margin of -3.53% compared to Tandem Diabetes Care's net margin of -9.20%. iRhythm Technologies' return on equity of -10.26% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

iRhythm Technologies has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Summary

iRhythm Technologies beats Tandem Diabetes Care on 11 of the 15 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Warby Parker?

Tandem Diabetes Care (NASDAQ:TNDM) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, Warby Parker had 9 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 10 mentions for Warby Parker and 1 mentions for Tandem Diabetes Care. Warby Parker's average media sentiment score of 0.83 beat Tandem Diabetes Care's score of 0.00 indicating that Warby Parker is being referred to more favorably in the news media.

Company	Overall Sentiment
Tandem Diabetes Care	Neutral
Warby Parker	Positive

Warby Parker has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	0.97	-$204.71M	-$1.40	N/A
Warby Parker	$871.91M	3.16	$1.64M	$0.02	1,285.50

Tandem Diabetes Care currently has a consensus target price of $29.13, indicating a potential upside of 102.12%. Warby Parker has a consensus target price of $29.50, indicating a potential upside of 14.74%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.45
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

Tandem Diabetes Care has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Warby Parker has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

Warby Parker has a net margin of 0.15% compared to Tandem Diabetes Care's net margin of -9.20%. Warby Parker's return on equity of 2.30% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
Warby Parker	0.15%	2.30%	1.18%

93.2% of Warby Parker shares are held by institutional investors. 2.1% of Tandem Diabetes Care shares are held by company insiders. Comparatively, 16.8% of Warby Parker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Warby Parker beats Tandem Diabetes Care on 13 of the 16 factors compared between the two stocks.

Get Tandem Diabetes Care News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNDM vs. The Competition

Export

Metric	Tandem Diabetes Care	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$982.71M	$6.95B	$6.46B	$12.11B
Dividend Yield	N/A	1.25%	2.68%	5.81%
P/E Ratio	-10.29	48.65	24.71	24.00
Price / Sales	0.97	46.53	492.47	90.40
Price / Cash	N/A	25.66	27.92	37.84
Price / Book	6.29	7.13	10.82	6.53
Net Income	-$204.71M	$159.20M	$3.56B	$336.99M
7 Day Performance	-13.66%	-1.41%	1.67%	-0.22%
1 Month Performance	-3.74%	-1.97%	0.43%	0.77%
1 Year Performance	-28.73%	7.94%	32.84%	31.57%

Tandem Diabetes Care Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNDM Tandem Diabetes Care	1.8618 of 5 stars	$14.41 +0.5%	$29.13 +102.1%	-29.1%	$982.71M	$1.01B	N/A	2,500	Analyst Forecast
LIVN LivaNova	2.1785 of 5 stars	$79.70 +0.4%	$79.38 -0.4%	+73.0%	$4.36B	$1.39B	40.87	3,300	Analyst Forecast
MMED MiniMed Group	3.8554 of 5 stars	$15.00 -1.1%	$21.33 +42.2%	N/A	$4.21B	$2.99B	N/A	8,000
NVST Envista	2.3692 of 5 stars	$24.68 +0.3%	$28.67 +16.2%	+35.1%	$4.00B	$2.72B	60.19	12,000
IRTC iRhythm Technologies	4.185 of 5 stars	$113.76 +0.1%	$187.38 +64.7%	-28.2%	$3.73B	$747.14M	N/A	2,400	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNDM) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tandem Diabetes Care (TNDM) Competitors

TNDM vs. LIVN, MMED, NVST, IRTC, and WRBY

How does Tandem Diabetes Care compare to LivaNova?

Summary

How does Tandem Diabetes Care compare to MiniMed Group?

Summary

How does Tandem Diabetes Care compare to Envista?

Summary

How does Tandem Diabetes Care compare to iRhythm Technologies?

Summary

How does Tandem Diabetes Care compare to Warby Parker?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM vs. The Competition

Tandem Diabetes Care Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tandem Diabetes Care (TNDM) Competitors

TNDM vs. LIVN, MMED, NVST, IRTC, and WRBY

How does Tandem Diabetes Care compare to LivaNova?

Which has preferable valuation and earnings, TNDM or LIVN?

Which has more risk & volatility, TNDM or LIVN?

Do analysts prefer TNDM or LIVN?

Is TNDM or LIVN more profitable?

Do insiders and institutionals believe in TNDM or LIVN?

Does the media favor TNDM or LIVN?

Summary

How does Tandem Diabetes Care compare to MiniMed Group?

Do analysts recommend TNDM or MMED?

Is TNDM or MMED more profitable?

Do institutionals & insiders have more ownership in TNDM or MMED?

Does the media refer more to TNDM or MMED?

Which has better valuation & earnings, TNDM or MMED?

Summary

How does Tandem Diabetes Care compare to Envista?

Do analysts recommend NVST or TNDM?

Does the media prefer NVST or TNDM?

Is NVST or TNDM more profitable?

Which has higher valuation and earnings, NVST or TNDM?

Which has more risk & volatility, NVST or TNDM?

Summary

How does Tandem Diabetes Care compare to iRhythm Technologies?

Which has stronger earnings and valuation, IRTC or TNDM?

Do analysts rate IRTC or TNDM?

Does the media refer more to IRTC or TNDM?

Is IRTC or TNDM more profitable?

Which has more risk & volatility, IRTC or TNDM?

Summary

How does Tandem Diabetes Care compare to Warby Parker?

Does the media prefer TNDM or WRBY?

Which has higher earnings & valuation, TNDM or WRBY?

Do analysts rate TNDM or WRBY?

Which has more risk & volatility, TNDM or WRBY?

Is TNDM or WRBY more profitable?

Do insiders & institutionals believe in TNDM or WRBY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM vs. The Competition

Tandem Diabetes Care Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools